These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 23171802

  • 21. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C, Onuma Y, Magro M, de Boer S, Battes L, van Domburg RT, Boersma E, Serruys PW, Interventional Cardiologists of the Thoraxcenter (2000-2005).
    Catheter Cardiovasc Interv; 2010 Jul 01; 76(1):41-9. PubMed ID: 20310019
    [Abstract] [Full Text] [Related]

  • 22. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.
    Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2011 Aug 01; 4(8):887-95. PubMed ID: 21851904
    [Abstract] [Full Text] [Related]

  • 23. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
    Stiermaier T, Heinz A, Schloma D, Kleinertz K, Dänschel W, Erbs S, Linke A, Boudriot E, Lauer B, Schuler G, Thiele H, Desch S.
    Catheter Cardiovasc Interv; 2014 Feb 15; 83(3):418-24. PubMed ID: 23873579
    [Abstract] [Full Text] [Related]

  • 24. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B, Dou K, Yang Y, Lv S, Wang L, Wang H, Li Z, Wang L, Chen Y, Huo Y, Li W, Kirtane AJ, Gao R.
    EuroIntervention; 2012 Nov 22; 8(7):796-802. PubMed ID: 23171800
    [Abstract] [Full Text] [Related]

  • 25. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial.
    Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, Iñiguez A, SanRoman A, Alfonso F, Hernández-Antolín R, Angiolillo DJ, Bañuelos C, Escaned J, Gonzalo N, Fernández C, Macaya C, Sabaté M, DIABETES Investigators.
    EuroIntervention; 2013 Jul 22; 9(3):328-35. PubMed ID: 23518240
    [Abstract] [Full Text] [Related]

  • 26. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
    Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB.
    JACC Cardiovasc Interv; 2012 Jun 22; 5(6):626-35. PubMed ID: 22721657
    [Abstract] [Full Text] [Related]

  • 27. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B, Christiansen EH, Bøtker HE, Hansen HS, Ravkilde J, Thuesen L, Aarøe J, Villadsen AB, Terkelsen CJ, Krusell LR, Maeng M, Kristensen SD, Veien KT, Hansen KN, Junker A, Madsen M, Andersen SL, Jensen SE, Jensen LO, SORT OUT VI Investigators.
    JACC Cardiovasc Interv; 2017 Feb 13; 10(3):255-264. PubMed ID: 28109874
    [Abstract] [Full Text] [Related]

  • 28. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS, Ribeiro EE.
    EuroIntervention; 2012 May 15; 8(1):117-9. PubMed ID: 22580255
    [Abstract] [Full Text] [Related]

  • 29. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA, Rathod KS, Gallagher S, Weerackody R, Knight CJ, Rothman MT, Mathur A, Jain AK, Timmis AD, Wragg A.
    Catheter Cardiovasc Interv; 2013 May 15; 81(6):E237-44. PubMed ID: 22707383
    [Abstract] [Full Text] [Related]

  • 30. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH, Coleman PS, Stoler RC, Papadakos S, Cutlip DE, Mauri L, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2013 Apr 15; 6(4):325-33. PubMed ID: 23523453
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y, Colleran R, Kufner S, Giacoppo D, Rheude T, Michel J, Cassese S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators.
    Cardiovasc Diabetol; 2016 Sep 01; 15(1):124. PubMed ID: 27586678
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
    Costopoulos C, Latib A, Naganuma T, Sticchi A, Ferrarello S, Regazzoli D, Chieffo A, Figini F, Carlino M, Montorfano M, Naim C, Kawaguchi M, Gerasimou A, Giannini F, Godino C, Colombo A.
    Catheter Cardiovasc Interv; 2014 May 01; 83(6):889-95. PubMed ID: 23804318
    [Abstract] [Full Text] [Related]

  • 35. Gender difference on five-year outcomes of EXCEL biodegradable polymer-coated sirolimus-eluting stents implantation: results from the CREATE study.
    Zhang L, Qiao B, Han YL, Li Y, Xu K, Zhang QY, Yang LX, Liu HL, Xu B, Gao RL, for CREATE investigators.
    Chin Med J (Engl); 2013 Mar 01; 126(6):1039-45. PubMed ID: 23506575
    [Abstract] [Full Text] [Related]

  • 36. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 01; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Rheude T, Ibrahim T, Massberg S, Laugwitz KL, Kastrati A, Byrne RA, ISAR-TEST-5 Investigators.
    JACC Cardiovasc Interv; 2016 Apr 25; 9(8):784-792. PubMed ID: 27017366
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB, TARGET I Investigators.
    EuroIntervention; 2013 May 20; 9(1):75-83. PubMed ID: 23685298
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.